{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:48:58Z","timestamp":1760316538378,"version":"build-2065373602"},"reference-count":3,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2024,7,15]]},"abstract":"<jats:p>This news section offers <jats:italic>Cancer<\/jats:italic> readers timely information on events, public policy analysis, topical issues, and personalities. This issue features Dr Carl June, who recently participated on a panel with the FDA to discuss the next steps needed to expand CAR T\u2010cell therapy into areas other than blood cancers. In addition, articles discuss a new standard of care for bladder cancer and a novel hormone that is safe and effective in men receiving radiotherapy for prostate cancer.<\/jats:p>","DOI":"10.1002\/cncr.35420","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T05:06:25Z","timestamp":1719637585000},"page":"2406-2406","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First person profile: Dr Carl June"],"prefix":"10.1002","volume":"130","author":[{"given":"Mary Beth","family":"Nierengarten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"e_1_2_3_2_1","unstructured":"US Food and Drug Administration 2017 FDA approves tisagenlecleucel for B\u2010cell ALL and tocilizumab for cytokine release syndrome"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"volume-title":"Unlocking complex cell\u2010based gene therapies. Public meeting","year":"2024","key":"e_1_2_3_4_1"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:48:01Z","timestamp":1760287681000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35420"}},"subtitle":["<i>Dr June recently participated on a panel with the FDA to discuss the next steps needed to expand CAR T\u2010cell therapy into areas other than blood cancers.<\/i>"],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":3,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,15]]}},"alternative-id":["10.1002\/cncr.35420"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35420","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2024,6,29]]},"assertion":[{"value":"2024-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}